

**What is claimed is:**

- 5           1. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding short heterodimer partner-1, wherein said compound specifically hybridizes with and inhibits the expression of a nucleic acid molecule encoding short heterodimer partner-1.
- 10           2. The compound of claim 1 which is an antisense oligonucleotide.
- 15           3. The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 66, 71, 73, 74, 78, 79, 85, 86, 87, 88 or 89.
- 20           4. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
- 25           5. The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 30           7. The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 35

9. The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10. The compound of claim 2 wherein the antisense  
5 oligonucleotide is a chimeric oligonucleotide.

11. A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding short  
10 heterodimer partner-1.

12. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

15 13. The composition of claim 12 further comprising a colloidal dispersion system.

14. The composition of claim 12 wherein the compound is an antisense oligonucleotide.  
20

15. A method of inhibiting the expression of short heterodimer partner-1 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of short heterodimer partner-1 is  
25 inhibited.

16. A method of treating an animal having a disease or condition associated with short heterodimer partner-1 comprising administering to said animal a therapeutically or  
30 prophylactically effective amount of the compound of claim 1 so that expression of short heterodimer partner-1 is inhibited.

17. The method of claim 16 wherein the condition  
35 involves abnormal lipid metabolism.

18. The method of claim 16 wherein the condition involves abnormal cholesterol metabolism.

19. The method of claim 16 wherein the condition is  
5 atherosclerosis.

20. The method of claim 16 wherein the disease is cardiovascular disease.